Nano-curcumin’s suppression of breast cancer cells (MCF7) through the inhibition of cyclinD1 expression

Sare Hosseini,1 Jamshidkhan Chamani,2 Mohammad Reza Hadipanah,3 Negar Ebadpour,4 Amir Sajjad Hojjati,4 Mohammad Hasan Mohammadzadeh,2 Hamid Reza Rahimi5,6 1Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; 2Department of Biology, Faculty of Sciences, Islamic Azad Univers...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hosseini S, Chamani J, Hadipanah MR, Ebadpour N, Hojjati AS, Mohammadzadeh MH, Rahimi HR
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	Nano-curcumin cyclinD1 MCF7 patient survival viability Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/9b6cbee59a804a3b9282c266464ff4a7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9b6cbee59a804a3b9282c266464ff4a7
record_format	dspace
spelling	oai:doaj.org-article:9b6cbee59a804a3b9282c266464ff4a72021-12-02T09:06:39ZNano-curcumin’s suppression of breast cancer cells (MCF7) through the inhibition of cyclinD1 expression1179-1314https://doaj.org/article/9b6cbee59a804a3b9282c266464ff4a72019-03-01T00:00:00Zhttps://www.dovepress.com/nano-curcumins-suppression-of-breast-cancer-cells-mcf7-through-the-inh-peer-reviewed-article-BCTThttps://doaj.org/toc/1179-1314Sare Hosseini,1 Jamshidkhan Chamani,2 Mohammad Reza Hadipanah,3 Negar Ebadpour,4 Amir Sajjad Hojjati,4 Mohammad Hasan Mohammadzadeh,2 Hamid Reza Rahimi5,6 1Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; 2Department of Biology, Faculty of Sciences, Islamic Azad University, Mashhad Branch, Mashhad, Iran; 3Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; 4Department of Laboratory Sciences, School of Paramedical Sciences, Mashhad University of Medical Sciences, Mashhad, Iran; 5Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; 6Department of Modern Sciences and Technologies, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran Background: Breast cancer is the leading cause of cancer worldwide. The high expenses associated with chemotherapy as well as its side effects make the management of breast cancer a daunting challenge. The most common overexpressed gene in breast cancer is cyclinD1, which induces cell proliferation. Recent investigations into cancer treatment have revealed that curcumin demonstrates potential anti-cancer properties through different pathways. However, the oral bioavailability of curcumin is negligible due to its high hydrophobic structure. Nanotechnology has been employed to overcome this barrier. Nano-formulated curcumin (SinaCurcumin®) has been shown to provide a significantly higher bioavailability for oral consumption. However, the efficacy of this nano-formulated drug in breast cancer has not yet been determined. In relation to the breast cancer cell line, the present study compared nano-curcumin’s anti-cancer properties with those of cyclophosphamide, adriamycin, and 5-fluorouracil (CAF). Methods: After treating MCF7 with nano-curcumin and CAF, the present work assessed cell viability via an MTT assay. The effects of these drugs on cyclinD1 expression were measured by real-time PCR. SPSS 16.0 was used to perform ANOVA and multiple range tests. Results: Nano-curcumin and the CAF regimen both lowered the viability of MCF7. Nano-curcumin decreased cell proliferation by 83.6%, which was more than that achieved by cyclophosphamide (63.31%), adriamycin (70.75%), and 5-fluorouracil (75.04%). In addition, curcumin was able to significantly reduce the expression of cyclinD1, whereas CAF did not alter cyclinD1 expression. Conclusion: Nano-curcumin has a relatively high cytotoxic effect on MCF7 breast cancer cells, suppressing the expression of cyclinD1, a critical gene in the development and metastasis of breast cancer. The current study demonstrated that nano-curcumin can be an effective drug in the CAF regimen for the treatment of breast cancer. However, further in vivo research is needed for determining its efficacy and safety in clinical applications. Keywords: nano-curcumin, cyclinD1, MCF7, patient survival, viabilityHosseini SChamani JHadipanah MREbadpour NHojjati ASMohammadzadeh MHRahimi HRDove Medical PressarticleNano-curcumincyclinD1MCF7patient survivalviabilityNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast Cancer: Targets and Therapy, Vol Volume 11, Pp 137-142 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Nano-curcumin cyclinD1 MCF7 patient survival viability Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Nano-curcumin cyclinD1 MCF7 patient survival viability Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Hosseini S Chamani J Hadipanah MR Ebadpour N Hojjati AS Mohammadzadeh MH Rahimi HR Nano-curcumin’s suppression of breast cancer cells (MCF7) through the inhibition of cyclinD1 expression
description	Sare Hosseini,1 Jamshidkhan Chamani,2 Mohammad Reza Hadipanah,3 Negar Ebadpour,4 Amir Sajjad Hojjati,4 Mohammad Hasan Mohammadzadeh,2 Hamid Reza Rahimi5,6 1Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; 2Department of Biology, Faculty of Sciences, Islamic Azad University, Mashhad Branch, Mashhad, Iran; 3Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; 4Department of Laboratory Sciences, School of Paramedical Sciences, Mashhad University of Medical Sciences, Mashhad, Iran; 5Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; 6Department of Modern Sciences and Technologies, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran Background: Breast cancer is the leading cause of cancer worldwide. The high expenses associated with chemotherapy as well as its side effects make the management of breast cancer a daunting challenge. The most common overexpressed gene in breast cancer is cyclinD1, which induces cell proliferation. Recent investigations into cancer treatment have revealed that curcumin demonstrates potential anti-cancer properties through different pathways. However, the oral bioavailability of curcumin is negligible due to its high hydrophobic structure. Nanotechnology has been employed to overcome this barrier. Nano-formulated curcumin (SinaCurcumin®) has been shown to provide a significantly higher bioavailability for oral consumption. However, the efficacy of this nano-formulated drug in breast cancer has not yet been determined. In relation to the breast cancer cell line, the present study compared nano-curcumin’s anti-cancer properties with those of cyclophosphamide, adriamycin, and 5-fluorouracil (CAF). Methods: After treating MCF7 with nano-curcumin and CAF, the present work assessed cell viability via an MTT assay. The effects of these drugs on cyclinD1 expression were measured by real-time PCR. SPSS 16.0 was used to perform ANOVA and multiple range tests. Results: Nano-curcumin and the CAF regimen both lowered the viability of MCF7. Nano-curcumin decreased cell proliferation by 83.6%, which was more than that achieved by cyclophosphamide (63.31%), adriamycin (70.75%), and 5-fluorouracil (75.04%). In addition, curcumin was able to significantly reduce the expression of cyclinD1, whereas CAF did not alter cyclinD1 expression. Conclusion: Nano-curcumin has a relatively high cytotoxic effect on MCF7 breast cancer cells, suppressing the expression of cyclinD1, a critical gene in the development and metastasis of breast cancer. The current study demonstrated that nano-curcumin can be an effective drug in the CAF regimen for the treatment of breast cancer. However, further in vivo research is needed for determining its efficacy and safety in clinical applications. Keywords: nano-curcumin, cyclinD1, MCF7, patient survival, viability
format	article
author	Hosseini S Chamani J Hadipanah MR Ebadpour N Hojjati AS Mohammadzadeh MH Rahimi HR
author_facet	Hosseini S Chamani J Hadipanah MR Ebadpour N Hojjati AS Mohammadzadeh MH Rahimi HR
author_sort	Hosseini S
title	Nano-curcumin’s suppression of breast cancer cells (MCF7) through the inhibition of cyclinD1 expression
title_short	Nano-curcumin’s suppression of breast cancer cells (MCF7) through the inhibition of cyclinD1 expression
title_full	Nano-curcumin’s suppression of breast cancer cells (MCF7) through the inhibition of cyclinD1 expression
title_fullStr	Nano-curcumin’s suppression of breast cancer cells (MCF7) through the inhibition of cyclinD1 expression
title_full_unstemmed	Nano-curcumin’s suppression of breast cancer cells (MCF7) through the inhibition of cyclinD1 expression
title_sort	nano-curcumin’s suppression of breast cancer cells (mcf7) through the inhibition of cyclind1 expression
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/9b6cbee59a804a3b9282c266464ff4a7
work_keys_str_mv	AT hosseinis nanocurcuminrsquossuppressionofbreastcancercellsmcf7throughtheinhibitionofcyclind1expression AT chamanij nanocurcuminrsquossuppressionofbreastcancercellsmcf7throughtheinhibitionofcyclind1expression AT hadipanahmr nanocurcuminrsquossuppressionofbreastcancercellsmcf7throughtheinhibitionofcyclind1expression AT ebadpourn nanocurcuminrsquossuppressionofbreastcancercellsmcf7throughtheinhibitionofcyclind1expression AT hojjatias nanocurcuminrsquossuppressionofbreastcancercellsmcf7throughtheinhibitionofcyclind1expression AT mohammadzadehmh nanocurcuminrsquossuppressionofbreastcancercellsmcf7throughtheinhibitionofcyclind1expression AT rahimihr nanocurcuminrsquossuppressionofbreastcancercellsmcf7throughtheinhibitionofcyclind1expression
_version_	1718398260481097728

Nano-curcumin&rsquo;s suppression of breast cancer cells (MCF7) through the inhibition of cyclinD1 expression

Ejemplares similares

Nano-curcumin’s suppression of breast cancer cells (MCF7) through the inhibition of cyclinD1 expression